1308384-58-8 Usage
General Description
Imidazo[1,2-b]pyridazine-3-carboxylic acid is a chemical compound with the molecular formula C8H5N3O2. It is a heterocyclic compound that contains both imidazole and pyridazine rings, with a carboxylic acid functional group attached at the 3-position. IMidazo[1,2-b]pyridazine-3-carboxylic acid has potential applications in medicinal chemistry, particularly in the development of pharmaceutical drugs. It may possess biological activities such as anti-inflammatory, antimicrobial, or antitumor properties and could be used as a building block for the synthesis of new drug candidates. Further research into the properties and potential uses of imidazo[1,2-b]pyridazine-3-carboxylic acid is ongoing in the field of chemical and pharmaceutical sciences.
Check Digit Verification of cas no
The CAS Registry Mumber 1308384-58-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,0,8,3,8 and 4 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1308384-58:
(9*1)+(8*3)+(7*0)+(6*8)+(5*3)+(4*8)+(3*4)+(2*5)+(1*8)=158
158 % 10 = 8
So 1308384-58-8 is a valid CAS Registry Number.
1308384-58-8Relevant articles and documents
Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties
Lee, Jung Wuk,Park, Jiwon,Kim, Jina,Kim, Jihyung,Choi, Changyu,Min, Kyung Hoon
, (2021/03/14)
Tumor-associated macrophages (TAMs) are predominantly associated with tumor growth. Colony-stimulating factor 1 receptor (CSF1R) acts as a key regulator of TAM survival and differentiation and is a molecular target for cancer therapies. Herein, novel CSF1
AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF
-
Page/Page column 70; 72, (2013/04/10)
The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont
